Screener
ANI Pharmaceuticals ANIP Generics and Other — Other (expense)income , net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
| (in thousands) | Generics and Other | Rare Disease and Brands | Corporate and Unallocated | Total |
|---|---|---|---|---|
| Selling, general, and administrative expense | 1,578 | 60,719 | 29,364 | 91,661 |
| Depreciation and amortization | — | — | 19,640 | 19,640 |
| Contingent consideration fair value adjustment | — | — | (622) | (622) |
| Operating Income (Loss) | $36,494 | $52,348 | $(48,382) | $40,460 |
| Unrealized gain on investment in equity securities | — | — | $741 | $741 |
| Interest expense, net | — | — | (3,636) | (3,636) |
| Other expense, net | — | — | (468) | (468) |
| Income (Loss) Before Income Tax Expense | $36,494 | $52,348 | $(51,745) | $37,097 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is ANI Pharmaceuticals's generics and other — other (expense)income , net?
- ANI Pharmaceuticals (ANIP) reported generics and other — other (expense)income , net of $0 in Q2 2026.
- What does generics and other — other (expense)income , net mean?
- Includes miscellaneous non-operating income or expenses that do not fit into standard categories like interest or taxes, such as foreign exchange gains or losses. It provides a view into peripheral financial events that impact the segment's overall net contribution.
Ask your AI about ANI Pharmaceuticals's generics and other — other (expense)income , net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude